Morgan Stanley Maintains Biogen at Equal-Weight, Raises Target to $238

Morgan Stanley raised its price target from $231 to $238, a 3.0% increase, while maintaining its Equal-Weight rating. The target implies 2.5% downside from Biogen's Oct. 28 close of $244.05.